Quote this publication Share Print

BYETTA (exenatide), antidiabetic

DIABETOLOGY - New indication
Opinions on drugs - Posted on Feb 23 2015

Reason for request

extension of indication

No clinical benefit demonstrated in combination with a basal insulin and metformin

 

  • BYETTA has Marketing Authorisation in triple therapy, in combination with a basal insulin and metformin in adults who have not achieved adequate glycaemic control with these medicinal products in triple therapy.
  • This use is set down in a specialist opinion justifying the escalation of treatment for the management of type 2 diabetes.

Actual benefit

Important

Substantial in the treatment of type 2 diabetes as adjunctive therapy to basal insulin with metformin in adults who have not achieved adequate glycaemic control with these agents.


Improvement in actual benefit

V (absence)

In combination with basal insulin and metformin in patients with type 2 diabetes inadequately controlled by these medicines, taking into account the data available, namely a non-inferiority study of exenatide versus insulin lispro, BYETTA does not provide any improvement in actual benefit (level V, non-existent).